Anixa Biosciences Inc
ANIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000715446
In the last 90 days, Anixa Biosciences Inc insiders filed 15 open-market purchases and 0 sales; 63 institutions reported holding it in 13F filings for Q2 2026, worth $15.0M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Anixa Biosciences Inc changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 58 | 53 | −5 |
| Shares | 5.28M | 5.57M | +281.9K (+5.3%) |
| Value | $16.5M | $12.3M | −$4.19M (−25.4%) |
New holders (5)
Institutions that held Anixa Biosciences Inc at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| D.A. Davidson & Co. | 736,415 | $1.63M | 0.01% |
| Robertson Stephens Wealth Management, LLC | 25,649 | $56.7K | 0.00% |
| Atria Wealth Solutions, Inc. | 24,000 | $53.0K | 0.00% |
| Concorde Asset Management, LLC | 13,969 | $30.9K | 0.02% |
| LifePro Asset Management | 10,760 | $23.8K | 0.02% |
Sold out (10)
Institutions that held Anixa Biosciences Inc at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Jane Street Group, LLC | 121,924 | $380.4K |
| Renaissance Technologies LLC | 68,800 | $215.0K |
| Citadel Advisors LLC | 38,254 | $119.4K |
| Marshall Wace, LLP | 26,372 | $82.3K |
| Goldman Sachs Group Inc | 20,501 | $64.0K |
| Cubist Systematic Strategies, LLC | 16,655 | $52.0K |
| Virtu Financial LLC | 16,156 | $50.0K |
| Squarepoint Ops LLC | 15,897 | $49.6K |
| Citigroup Inc | 2,087 | $6.51K |
| FMR LLC | 250 | $780 |